Psychedelics hold promise for primary care research

A renewed interest in the therapeutic potential of psychoactive drugs such as psilocybin, mescaline, and lysergic acid diethylamide is underway, termed the 'psychedelic renaissance.' These substances were initially greeted with exuberance in the mid-20th century for their apparent panacea-like effects on conditions like depression, anxiety, PTSD, and existential grief in terminal cancer patients. However, their association with the counterculture movement led to research suppression by political forces aligned with the 'War on Drugs.' The field has now reached a watershed moment, with psychedelic research becoming mainstream and psilocybin receiving 'Breakthrough Therapy' status.

Study at a glance

Abstract

Dear Editor, We are in the midst of a so-called “psychedelic renaissance,” a time of renewed interest in the therapeutic potential of psychoactive drugs such as psilocybin, mescaline, and lysergic acid diethylamide. When they first emerged as topics of academic interest in the mid-20th century, these substances were greeted with exuberance for their apparent panacea-like effects in treating a range of conditions from depression and anxiety to post-traumatic stress disorder to existential grief in terminal cancer patients. Despite their promise, these compounds became associated with the counterculture movement in the public imagination and research was suppressed by political forces aligned with the so-called “War on Drugs.” It seems, however, that we have reached a watershed moment as psychedelic research has reemerged and even become mainstream, reaching the front page of the New York Times in May of this year.1 Already, psilocybin has been granted “Breakthrough Therapy” status by the...